EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
EyePoint Pharmaceuticals (EYPT) Prices 9.1M Share Common Offering at $11/Sh
February 2, 2021 5:48 AM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public... More
Pre-Open Stock Movers 01/28: (KOSS) (HIMS) (EYPT) Higher; (AMC) (BBY) (NOK) (EXPR) Lower (more...)
January 28, 2021 9:29 AM ESTPre-pen Stock Movers
Koss Corporation (NASDAQ: KOSS) 78% HIGHER; adds to recent short-squeeze gains.
AMC Entertainment Holdings, Inc. (NYSE: AMC) 35.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze. Trading firms restrict trading.
Him & Hers Health (NYSE:... More
EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
January 28, 2021 7:10 AM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
EYP-1901 leverages the Companys proprietary Durasert® drug delivery technology that has been used in four FDA-approved products, including EyePoints YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. EYP-1901 uses a bioerodible Durasert formulation combined with a clinically validated anti-VEGF molecule, vorolanib. In oral formulation, vorolanib demonstrated efficacy and... More
